Nkarta (NKTX) Competitors $2.12 -0.05 (-2.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.08 -0.04 (-2.12%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. ARVN, RAPP, ATYR, OPT, PGEN, SLDB, TERN, TRML, PRTC, and SIGAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Arvinas (ARVN), Rapport Therapeutics (RAPP), aTyr Pharma (ATYR), Opthea (OPT), Precigen (PGEN), Solid Biosciences (SLDB), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), PureTech Health (PRTC), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Arvinas Rapport Therapeutics aTyr Pharma Opthea Precigen Solid Biosciences Terns Pharmaceuticals Tourmaline Bio PureTech Health Siga Technologies Arvinas (NASDAQ:ARVN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Is ARVN or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-10.92% -7.74% -4.11% Nkarta N/A -26.64%-21.62% Which has more risk and volatility, ARVN or NKTX? Arvinas has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Do analysts rate ARVN or NKTX? Arvinas presently has a consensus target price of $20.29, suggesting a potential upside of 173.44%. Nkarta has a consensus target price of $14.33, suggesting a potential upside of 576.10%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Which has preferable earnings and valuation, ARVN or NKTX? Nkarta has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.06-$198.90M-$0.66-11.24NkartaN/AN/A-$108.79M-$1.51-1.40 Does the media refer more to ARVN or NKTX? In the previous week, Arvinas had 1 more articles in the media than Nkarta. MarketBeat recorded 4 mentions for Arvinas and 3 mentions for Nkarta. Nkarta's average media sentiment score of 1.15 beat Arvinas' score of 0.17 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Nkarta 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ARVN or NKTX? 95.2% of Arvinas shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 8.4% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryArvinas and Nkarta tied by winning 8 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.43M$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-1.406.3119.2822.29Price / SalesN/A309.96440.8796.30Price / CashN/A41.6335.0757.18Price / Book0.378.488.255.54Net Income-$108.79M-$55.06M$3.25B$259.88M7 Day Performance-1.85%-3.99%-3.73%-4.66%1 Month Performance21.84%9.58%4.28%4.40%1 Year Performance-64.49%6.70%25.85%17.92% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.3195 of 5 stars$2.12-2.3%$14.33+576.1%-66.9%$150.43MN/A-1.40140News CoveragePositive NewsARVNArvinas3.4809 of 5 stars$7.52+2.3%$20.29+169.8%-72.3%$536.49M$263.40M-11.39420News CoverageUpcoming EarningsRAPPRapport Therapeutics1.2198 of 5 stars$14.39-2.0%$28.00+94.6%-31.0%$535.79MN/A-4.17N/AATYRaTyr Pharma2.5877 of 5 stars$5.71-4.7%$20.20+253.8%+141.0%$533.14M$230K-7.0553Options VolumeGap DownHigh Trading VolumeOPTOpthea0.3817 of 5 stars$3.41+7.2%$1.33-60.9%+53.2%$524.84M$120K0.008Gap UpPGENPrecigen3.9929 of 5 stars$1.83+4.0%$6.00+227.9%+16.8%$519.52M$3.92M-3.27190News CoveragePositive NewsOptions VolumeSLDBSolid Biosciences2.668 of 5 stars$6.37-0.3%$15.10+137.0%-20.9%$495.32M$8.09M-2.13100Positive NewsGap UpHigh Trading VolumeTERNTerns Pharmaceuticals3.6877 of 5 stars$5.64flat$15.63+177.0%-29.6%$492.58MN/A-5.1740Upcoming EarningsTRMLTourmaline Bio1.5654 of 5 stars$18.23-1.4%$49.33+170.6%+33.2%$474.67MN/A-5.6844Upcoming EarningsPRTCPureTech Health1.4294 of 5 stars$18.56+0.3%$45.00+142.4%-12.1%$472.52M$4.83M0.00100Gap DownSIGASiga Technologies1.8555 of 5 stars$6.85+3.6%N/A-30.1%$472.23M$138.72M10.2240 Related Companies and Tools Related Companies Arvinas Competitors Rapport Therapeutics Competitors aTyr Pharma Competitors Opthea Competitors Precigen Competitors Solid Biosciences Competitors Terns Pharmaceuticals Competitors Tourmaline Bio Competitors PureTech Health Competitors Siga Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTX Stock Alerts